Abstract: The present invention provides a cochlear outer hair cell (OHC) regenerated by ectopic joint overexpression of Atoh1 and Ikzf2 and an application thereof. Specifically, the present invention provides an active ingredient combination capable of being used for regenerating a cochlear OHC, and a use thereof. The active ingredient combination comprises an Ikzf2 protein and an Atoh1 protein; and after the active ingredient combination is administered to a subject suffering from hearing impairment related to cochlear OHC degeneration and/or injury, hearing impairment can be alleviated by regenerating an OHC-like cell. A new method is provided for clinical treatment of hearing impairment.

Abstract: Described herein are bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof that can include a bisphosphonate and a quinolone, where the quinolone can be releasably coupled to the bisphosphonate. Also provided herein are methods of making and methods of using the bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof.

Abstract: A method for determining a full-charge capacity of a battery pack includes: obtaining first state of charge values of cells at a first state of charge correction moment; calculating a net cumulative charge capacity from the first state of charge correction moment to a full-charge moment; obtaining a voltage-capacity curve of a fully charged cell from start of a charge termination phase to the full-charge moment; obtaining a second voltage of a not fully charged cell at the full-charge moment; obtaining a capacity difference between the not fully charged cell at the full-charge moment and the not fully charged cell at the first full-charge voltage; calculating a state of charge difference; calculating a second state of charge value of the not fully charged cell at the full-charge moment; obtaining state of charge variations; calculating full-charge capacities; and obtaining a full-charge capacity based on the calculated full-charge capacities.

Abstract: A discharging control method and a charging control method for a battery pack control system are provides. The battery pack control system includes a master battery management unit and multiple slave battery management units. The master battery management unit controls the slave battery management units. The slave battery management units controls battery packs to connect to an operating circuit or disconnect from the operating circuit. In the discharging control method and the charging control method, a loop current generated from connecting a battery pack to an operating circuit is predicted each time before a slave battery management unit controls the battery pack to connect to the operating circuit, and the battery pack is controlled to connect to the operating circuit with the generated loop current within a safe value range.

Abstract: This application discloses a charging duration determining method, a BMS, a battery, and an electrical device. The method includes: determining a charge temperature of a battery; estimating, in a case that the charge temperature exceeds a first specified range, a first duration to be taken to adjust the charge temperature of the battery to the first specified range; estimating a second duration to be taken to charge the battery to a target SOC after the charge temperature of the battery has been adjusted to the first specified range; and determining, based on a charge start time of the battery, the first duration, and the second duration, a duration to be taken to charge the battery to the target SOC. The charging duration determined for the battery according to this application is more accurate, and facilitates users to accurately learn the charging status of the battery in time.

Abstract: A method for determining a charging time includes obtaining a maximum monomer voltage of a cell of a battery, and under a condition that the maximum monomer voltage is determined to be greater than or equal to a value, determining, based on a charging voltage of the battery, the charging time of the battery.

Abstract: A method for determining a remaining charging time of a battery. The method includes obtaining a first charging current and a second charging current. The first charging current is a present charging current of the battery, and the second charging current is a charging current of the battery when the battery is fully charged. The method further includes determining an average charging current value based on the first charging current and the second charging current, and determining the remaining charging time based on the average charging current value.

Abstract: A method for determining a full-charge capacity of a battery pack includes: obtaining first state of charge values of cells at a first state of charge correction moment; calculating a net cumulative charge capacity from the first state of charge correction moment to a full-charge moment; obtaining a voltage-capacity curve of a fully charged cell from start of a charge termination phase to the full-charge moment; obtaining a second voltage of a not fully charged cell at the full-charge moment; obtaining a capacity difference between the not fully charged cell at the full-charge moment and the not fully charged cell at the first full-charge voltage; calculating a state of charge difference; calculating a second state of charge value of the not fully charged cell at the full-charge moment; obtaining state of charge variations; calculating full-charge capacities; and obtaining a full-charge capacity based on the calculated full-charge capacities.

Abstract: This application provides a method and a device for estimating a remaining charging time of a battery, and a battery management system. The method includes: determining a minimum charging time of each type of battery cell at a Kth charging phase based on a charge request current value of each type of battery cell at the Kth charging phase; and determining the remaining charging time of the battery when the Kth charging phase of any type of battery cell in the battery is a target state-of-charge phase, where the remaining charging time of the battery is a smallest one of accumulation values, each accumulation value being an accumulation of minimum charging times of a type of battery cell in the battery at all charging phases.

Abstract: This application provides a method and a device for estimating a remaining charging time of a battery, and a battery management system. The method includes: determining a minimum charging time of each type of battery cell at a Kth charging phase based on a charge request current value of each type of battery cell at the Kth charging phase; and determining the remaining charging time of the battery when the Kth charging phase of any type of battery cell in the battery is a target state-of-charge phase, where the remaining charging time of the battery is a smallest one of accumulation values, each accumulation value being an accumulation of minimum charging times of a type of battery cell in the battery at all charging phases.

Abstract: This invention relates to drug conjugates useful for localized treatment of diseases or disorders of the middle ear and/or inner ear. Methods of treating diseases or disorders of the middle ear and/or inner ear, pharmaceutical compositions comprising the conjugates, and methods of inhibiting a Tropomyosin receptor kinase are also provided.

Abstract: Disclosed herein are methods and compositions for removing or displacing bisphosphonates in skeletal tissue.

Abstract: This invention relates to drug conjugates useful for localized treatment of diseases or disorders of the middle ear and/or inner ear. Methods of treating diseases or disorders of the middle ear and/or inner ear, pharmaceutical compositions comprising the conjugates, and methods of inhibiting a Tropomyosin receptor kinase are also provided.

Abstract: Described herein are bisphosphonate oxazolidinone compounds, and conjugates and pharmaceutical formulations thereof, that can include a bisphosphonate and an oxazolidinone (or an oxazolidinone antimicrobial or antibiotic agent, substituent or derivative thereof), where the oxazolidinone can be releasably coupled to the bisphosphonate. Also provided herein are methods of making and methods of using the bisphosphonate oxazolidinone compounds, conjugates and pharmaceutical formulations thereof. Also provided herein are methods of use of the compounds, conjugates and formulations for treating a bone disease or for use in preparing a formulation for the treatment a bone disease.

Abstract: Disclosed herein are methods and compositions for removing or displacing bisphosphonates in skeletal tissue.

Abstract: Described herein are bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof that can include a bisphosphonate and a quinolone, where the quinolone can be releasably coupled to the bisphosphonate. Also provided herein are methods of making and methods of using the bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof.

Abstract: Described herein are bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof that can include a bisphosphonate and a quinolone, where the quinolone can be releasably coupled to the bisphosphonate. Also provided herein are methods of making and methods of using the bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof.

Abstract: Disclosed herein are methods and compositions for removing or displacing bisphosphonates in skeletal tissue.

Abstract: Disclosed herein are methods and compositions for removing or displacing bisphosphonates in skeletal tissue.

Abstract: Described herein are bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof that can include a bisphosphonate and a quinolone, where the quinolone can be releasably coupled to the bisphosphonate. Also provided herein are methods of making and methods of using the bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof.